Novus Therapeutics, Inc. — 2017 Form 10-K Summary
Filing identity and period: The supplied filing is Novus Therapeutics, Inc.’s annual report for the fiscal year ended December 31, 2017, filed March 30, 2018. It is not identified as an Eledon Pharmaceuticals filing, and it reports annual results rather than standalone fourth-quarter results.
Business context
Novus was a development-stage specialty pharmaceutical company focused on ear, nose and throat disorders. Its lead candidate, OP-02, is an intranasal surfactant combination in development for otitis media and Eustachian tube dysfunction. OP-01, a foam-based treatment platform initially studied for swimmer’s ear, was paused as resources shifted to OP-02. Novus had no approved products and had not generated product revenue.
On May 9, 2017, Tokai Pharmaceuticals completed a reverse merger with Otic Pharma; Otic was the accounting acquirer. The surviving company changed its name to Novus Therapeutics and effected a one-for-nine reverse stock split.
Financial performance and liquidity
| Metric | FY 2017 | FY 2016 | Change / context |
|---|---|---|---|
| Revenue | No product revenue | No product revenue | Development-stage company |
| Research and development expense | $2.022 million | $3.191 million | Down 37%; 2017 included OP-02 formulation work and legacy Tokai program closeout |
| General and administrative expense | $11.099 million | $1.937 million | Up 473%, including $4.0 million merger costs, higher public-company costs and legal expenses |
| Total operating expenses | $13.121 million | $5.128 million | Up 156% |
| Net loss | $13.116 million | $5.655 million | Loss increased $7.461 million |
| Net loss per share, basic and diluted | $2.30 | $2.46 | Weighted-average shares differed materially following the merger and share transactions |
| Net cash used in operating activities | $14.941 million | $4.923 million | Higher cash use reflected operating loss and working-capital changes |
| Cash, cash equivalents and restricted cash at year-end | $17.303 million | $1.117 million | Included $23.250 million received in the merger |
| Working capital | $17.6 million | Not stated here | As of December 31, 2017 |
| Total liabilities | $1.440 million | $3.898 million | Convertible notes of $3.447 million at 2016 year-end had converted to common stock in 2017; no convertible notes remained at 2017 year-end |
No operating margin is meaningful because the company reported no product revenue. The filing reports no debt balance at December 31, 2017. The company said its available cash was expected to fund operations for at least 12 months from issuance of the financial statements, but additional funding would be needed to complete development and commercialization.
Material changes and financing
- Novus received $23.250 million in cash through the reverse merger and raised approximately $4.0 million in a May 2017 private placement.
- Warrant exercises generated approximately $3.119 million during 2017. The company also sold 167,356 shares under its at-the-market facility through year-end, for approximately $0.774 million gross proceeds.
- After year-end, the company completed the $8.5 million at-the-market program: from October 2017 through March 9, 2018, it sold 2,463,966 shares for approximately $8.5 million gross proceeds. These post-year-end sales are not part of 2017 cash flow.
- The 2017 net loss included a major increase in general and administrative expenses, including merger-related costs and costs of being a public company. Other income/expense improved as the prior-year convertible-note fair-value adjustment did not recur after conversion.
- The company reported $112,000 of remaining operating lease payments, all due within one year, and no off-balance-sheet arrangements.
Outlook, risks and contingencies
- Management expected to begin OP-02 Phase 1 studies in 2018, conditional on completing formulation development and producing a clinical-grade cGMP batch. The filing states no such batch had yet been manufactured. Planned studies included repeated dosing in healthy subjects and additional patient studies; later-stage trials remained contingent on results.
- OP-02 had not been evaluated in human clinical studies. Preclinical animal findings and limited historical case reports do not establish human safety or efficacy. Development, regulatory approval and commercialization were uncertain and could take years.
- Novus depended on external manufacturers and CROs, lacked redundant supply arrangements, and had not qualified a secondary supplier for OP-02’s active ingredients. Its license for OP-02 carries potential development/regulatory milestones of up to $42.1 million, sales milestones up to $36 million, and tiered royalties.
- The company expected continuing losses and stated that additional financing might be required. Financing may not be available on acceptable terms and could dilute stockholders or force development delays or reductions.
- Several securities lawsuits related to Tokai’s prior galeterone clinical disclosures and IPO remained unresolved. The company said it could not predict outcomes or estimate a reasonably possible loss range; no liability was accrued for contingencies at year-end.
- Israeli Innovation Authority grants of approximately $537,000 are repayable through royalties if products developed with the funding generate sales; no repayment liability was recorded because there were no such sales. The company also disclosed possible limits on the use of tax-loss carryforwards following ownership changes.
- Management reported effective disclosure controls and effective internal control over financial reporting as of December 31, 2017. The independent auditor issued an unqualified opinion on the 2017 financial statements but was not engaged to audit internal controls.
Most important facts for investors to verify
- Confirm the issuer: this filing is for Novus Therapeutics, Inc., not Eledon Pharmaceuticals, Inc.
- Check subsequent filings for OP-02 clinical start, cGMP manufacturing readiness, trial progress and any changes to development plans.
- Review current cash, cash burn and financing needs, including share dilution from the 2017–2018 ATM sales.
- Track the status and potential financial exposure of the Tokai-related securities litigation; the filing provides no loss estimate.
- Assess OP-02’s patent protection, supplier concentration and license economics, alongside the limited human evidence and substantial clinical/regulatory risks.